Exelixis

Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes small-molecule therapies for difficult-to-treat cancers. The enterprise discovered cabozantinib, marketed as Cabometyx and Cometriq, which serves as a cornerstone tyrosine kinase inhibitor for advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. Through strategic biopharma collaborations and internal drug discovery programs, Exelixis continually expands its targeted cancer therapy pipeline.